Innoviva, Inc. (INVA) News
Filter INVA News Items
INVA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
INVA News Highlights
- INVA's 30 day story count now stands at 2.
- Over the past 13 days, the trend for INVA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about INVA are DRUG.
Latest INVA News From Around the Web
Below are the latest news stories about INNOVIVA INC that investors may wish to consider to help them evaluate INVA as an investment opportunity.
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted AntibioticBURLINGAME, Calif., March 13, 2023--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review data supporting the new drug application (NDA) for sulbactam-durlobactam (SUL-DUR). |
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company ProgressBURLINGAME, Calif., February 28, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth quarter ended December 31, 2022. |
11 Most Undervalued Biotech Stocks To Buy According To Hedge FundsIn this article, we will take a look at the 11 most undervalued biotech stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds. The rising interest rate environment hammered the biotech industry in 2022. Small biotech companies need […] |
Shareholders in Innoviva (NASDAQ:INVA) are in the red if they invested a year agoInvestors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that... |
12 Most Undervalued Pharma Stocks To Buy According To Hedge FundsIn this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […] |
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLCArmata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement (the "credit agreement") with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross p |
Innoviva (INVA) Gains As Market Dips: What You Should KnowIn the latest trading session, Innoviva (INVA) closed at $13.27, marking a +0.15% move from the previous day. |
7 Undervalued Biotech Stocks to Buy Before They BoomWhile medical innovations offer tremendous appeal, investors can still get a discount in this sector via undervalued biotech stocks to buy. |
Innoviva (INVA) Stock Moves -1.06%: What You Should KnowIn the latest trading session, Innoviva (INVA) closed at $13.03, marking a -1.06% move from the previous day. |
Do Its Financials Have Any Role To Play In Driving Innoviva, Inc.'s (NASDAQ:INVA) Stock Up Recently?Most readers would already be aware that Innoviva's (NASDAQ:INVA) stock increased significantly by 11% over the past... |